Shattuck Labs
Shattuck Labs' revenue fell 82.5% to $1 million in fiscal 2025. Its operating margin was −5,150.8%, down from −1,408.3% a year earlier. Free cash flow was −$40 million. The diluted share count rose 37.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Shattuck Labs does
Shattuck Labs is a clinical-stage biotechnology company with no approved products. It develops antibodies that block a protein called Death Receptor 3, or DR3, to treat inflammatory and immune-mediated diseases. Its lead drug candidate, SL-325, is designed to block the DR3/TL1A pathway more fully than antibodies that target TL1A, the molecule that switches DR3 on.
SL-325 is in a Phase 1 trial in healthy volunteers, and Shattuck Labs expects to start a Phase 2 trial in patients with Crohn's disease in the third quarter of 2026. Shattuck Labs also has bispecific antibodies and other candidates still in preclinical work.
It has no product revenue. Its plan is to move SL-325 through trials and, if they succeed, seek approval to sell it. It competes with other companies that have developed or are developing drugs for the same diseases, including TL1A-blocking antibodies. Its claims that SL-325 may work better than those drugs are the company's own beliefs, based on its early lab studies.
Its biggest risks, as it describes them
- It needs more funding to finish developing its drugs, which could dilute shareholders.
- It depends heavily on one lead candidate, SL-325, which is in early clinical development.
- Trials may fail to show that its drugs are safe and work, or may be delayed by slow patient enrollment.
- Competition from other companies developing drugs for the same diseases.
- It has no approved products and has not completed any late-stage trial.
Income statement
Shattuck Labs lost money in fiscal 2025: a net loss of $49 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 269 | 161 | 131 | 73 | 78 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 11.7x | 7.4x | 12.5x | 8.9x | 11.7x |
| Quick ratio | 11.7x | 7.4x | 12.5x | 8.9x | 11.7x |
Cash flow
Projections
Project Shattuck Labs' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Shattuck Labs reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −4,772.5% | −813.5% | −4,077.8% |
| Altman Z'' | 5.51 | −7.23 | −3.77 |
| Accruals ratio | −3.3% | −11.9% | −9.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Shattuck Labs side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Shattuck Labs | FY25 | −82.5% | −5,150.8% | −3,995.3% | — | — | — | |
| Inhibrx Biosciences | FY25 | 550.0% | −10,386.5% | −9,986.5% | — | — | 2 | Compare |
| Z Squared | FY25 | — | −956.9% | — | — | — | — | Compare |
| Celldex Therapeutics | FY25 | −78.0% | −18,599.8% | −13,829.1% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 10 | 10 | 30 | 1 | 2 | 6 | 1 |
| Revenue growth | — | 0.5% | 202.2% | −97.8% | 154.1% | 245.3% | −82.5% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 29 | 38 | 57 | 83 | 74 | 67 | 35 |
| Operating income | −25 | −37 | −45 | −103 | −92 | −81 | −52 |
| Net income | −24 | −37 | −45 | −102 | −87 | −75 | −49 |
| Diluted EPS (US$) | −3.17 | −2.36 | −1.07 | −2.41 | −2.05 | −1.49 | −0.70 |
| Diluted shares (millions) | 8 | 16 | 42 | 42 | 43 | 51 | 70 |
| Cash flow | |||||||
| Cash from operations | −21 | −34 | −57 | −94 | −81 | −60 | −40 |
| Capital expenditure | 0 | 1 | 8 | 12 | 0 | 0 | 0 |
| Free cash flow | −21 | −34 | −65 | −106 | −82 | −61 | −40 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 6 | 6 | 7 | 10 | 7 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 39 | 335 | 269 | 161 | 131 | 73 | 78 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 45 | 349 | 299 | 205 | 160 | 91 | 91 |
| Total liabilities | 30 | 39 | 27 | 29 | 15 | 11 | 9 |
| Shareholders' equity | −34 | 310 | 272 | 176 | 145 | 80 | 82 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −253.5% | −371.8% | −150.8% | −15,848.0% | −5,549.6% | −1,408.3% | −5,150.8% |
| Net margin | −242.6% | −368.5% | −149.8% | −15,635.7% | −5,268.4% | −1,318.1% | −4,880.9% |
| Free cash flow margin | −216.9% | −346.1% | −216.7% | −16,274.9% | −4,926.7% | −1,058.8% | −3,995.3% |
| Rule of 40 (growth + FCF margin) | — | −345.7% | −14.5% | −16,372.7% | −4,772.5% | −813.5% | −4,077.8% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −26.6% | −15.5% | −45.5% | −54.4% | −67.2% | −60.2% |
| Return on assets | — | −18.6% | −13.9% | −40.5% | −47.9% | −60.2% | −53.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — |